News

Two studies examining relationships between measures of kidney function and adverse events after platinum-based chemotherapy were presented as late-breaking abstracts at the National Kidney Foundation ...
Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.
To develop the combined model, the researchers integrated the imaging-derived radiomics score from the best-performing radiomics model (random forest) with the clinical model.
The cohort study included more than a quarter million men with prostate cancer from routine clinical practice.
Predictors of longer postdiscontinuation progression-free survival include complete/partial response, longer treatment duration.
The most common projected cancers in adults were lung cancer, colon cancer, leukemia, bladder cancer, and stomach cancer.
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...
Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.
DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.
With a 95% retention rate for nurse residents completing the program and a 100% 2-year post-hire retention rate, these initiatives ensure a stable and well-trained workforce.
A team of researchers explain how navigation programs work, who benefits, and how to create a successful navigation program.
The phase 3 trial enrolled 1033 patients who had not received prior chemotherapy for mCRPC and had evidence of disease progression despite androgen deprivation therapy.